Scienture Holdings Inc (SCNX) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Scienture Holdings Inc   (NASDAQ: SCNX)

Select the Financial Report: Select the Period:


Description of Scienture Holdings Inc's Business Segments
As of December 31, 2025, the Company operates a single reportable and operating segment within the United States. The co-Chief Executive Officers serve as the chief operating decision-makers, making resource allocation decisions and assessing performance based on aggregate financial information. There are no segment managers responsible for planning, strategy, or key operational decisions. Key financial measures reviewed include total revenues, gross profit, total operating expenses (including research and development expenses), and net loss from continuing operations. Significant expenses reported to the chief operating decision-makers include research and development costs for SCN-102, SCN-104, SCN-106, and SCN-107, wage and salary expenses, professional fees, accounting and legal expenses, and non-cash impairment losses. Additional expenses comprise technology costs, general and administrative expenses (including stock-based compensation), and depreciation and amortization.

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Composition of Scienture Holdings Inc Revenues by Segments
 
Losartan Potassium Oral Suspension    100 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)		 %
(of total Revenues)
Losartan Potassium Oral Suspension 0.06 100 %
Total 0.06 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%		 Q/Q Revenue
%
Losartan Potassium Oral Suspension - -
Total 449.08 % -86.95 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)		 %
(Profit Margin)
Total -3.40 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%		 Q/Q Income
%
Total - -




Annual Report on Scienture Holdings Inc Divisions, Sales by Country

 
ARBLI Losartan Oral Potassium Suspension   ARBLI Losartan Oral Potassium Suspension Segment contribution to total sales 100 % of total Revenue


Twelve months ended 2025
SCNX s Annual Revenue by Geography and Business Segments Sales
(in millions $)		 %
(of total Sales)
Total 0.43 100 %
ARBLI Losartan Oral Potassium Suspension 0.43 100 %


Twelve months ended 2025
SCNX s Annual Income by Country and Business Segments Income
(in millions $)		 %
(Profit Margin)
Total -41.51 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Total 215.87 % -
Integra - -
UNITED STATES - -
Trxade Inc - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.